METHYLIN Drug Patent Profile

When do Methylin patents expire, and what generic alternatives are available?

Methylin is a drug marketed by Specgx Llc and is included in three NDAs.

The generic ingredient in METHYLIN is methylphenidate hydrochloride. There are thirty-two drug master file entries for this compound. Forty-five suppliers are listed for this compound. Additional details are available on the methylphenidate hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Methylin

A generic version of METHYLIN was approved as methylphenidate hydrochloride by SPECGX LLC on November 27^th, 1998.

Summary for METHYLIN

US Patents:	0
Applicants:	1
NDAs:	3
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	3
Patent Applications:	4,720
Drug Prices:	Drug price information for METHYLIN
What excipients (inactive ingredients) are in METHYLIN?	METHYLIN excipients list
DailyMed Link:	METHYLIN at DailyMed

See drug prices for METHYLIN

See drug sales revenues for METHYLIN

Recent Clinical Trials for METHYLIN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Nicoleta Stoicea	Phase 1
Dana-Farber Cancer Institute	Phase 1
Boston Children’s Hospital	Phase 1

See all METHYLIN clinical trials

Pharmacology for METHYLIN

Drug Class	Central Nervous System Stimulant
Physiological Effect	Central Nervous System Stimulation

Paragraph IV (Patent) Challenges for METHYLIN

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
METHYLIN	Oral Solution	methylphenidate hydrochloride	5 mg/5 mL 10 mg/5 mL	021419	1	2010-04-13

US Patents and Regulatory Information for METHYLIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Specgx Llc	METHYLIN	methylphenidate hydrochloride	SOLUTION;ORAL	021419-001	Dec 19, 2002	AA	RX	Yes	Yes
Specgx Llc	METHYLIN ER	methylphenidate hydrochloride	TABLET, EXTENDED RELEASE;ORAL	075629-002	May 9, 2000	AB	RX	No	No
Specgx Llc	METHYLIN	methylphenidate hydrochloride	TABLET, CHEWABLE;ORAL	021475-002	Apr 15, 2003		DISCN	Yes	No
Specgx Llc	METHYLIN	methylphenidate hydrochloride	SOLUTION;ORAL	021419-002	Dec 19, 2002	AA	RX	Yes	Yes
Specgx Llc	METHYLIN	methylphenidate hydrochloride	TABLET, CHEWABLE;ORAL	021475-001	Apr 15, 2003		DISCN	Yes	No
Specgx Llc	METHYLIN ER	methylphenidate hydrochloride	TABLET, EXTENDED RELEASE;ORAL	075629-001	May 9, 2000	AB	RX	No	No
Specgx Llc	METHYLIN	methylphenidate hydrochloride	TABLET, CHEWABLE;ORAL	021475-003	Apr 15, 2003		DISCN	Yes	No

Expired US Patents for METHYLIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Specgx Llc	METHYLIN	methylphenidate hydrochloride	SOLUTION;ORAL	021419-001	Dec 19, 2002	7,691,880
Specgx Llc	METHYLIN	methylphenidate hydrochloride	SOLUTION;ORAL	021419-002	Dec 19, 2002	7,691,880

International Patents for METHYLIN

See the table below for patents covering METHYLIN around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	1680144	SOLUTION DE METHYLPHENIDATE ET PROCEDES ASSOCIES D'ADMINISTRATION ET DE PRODUCTION (METHYLPHENIDATE SOLUTION AND ASSOCIATED METHODS OF ADMINISTRATION AND PRODUCTION)
Austria	526988
Mexico	PA06003725	SOLUCION DE FENIDATO DE METILO Y METODOS ASOCIADOS DE ADMINISTRACION Y PRODUCCION. (METHYLPHENIDATE SOLUTION AND ASSOCIATED METHODS OF ADMINISTRATION AND PRODUCTION.)
Spain	2373042
Canada	2540052	SOLUTION DE METHYLPHENIDATE ET PROCEDES ASSOCIES D'ADMINISTRATION ET DE PRODUCTION (METHYLPHENIDATE SOLUTION AND ASSOCIATED METHODS OF ADMINISTRATION AND PRODUCTION)
Japan	4959335
China	1867359	Methylphenidate solution and associated methods of administration and produciton

Market Dynamics and Financial Trajectory for Methylin (Methylphenidate)

Last updated: February 20, 2026

What is the current market size for Methylin?

Methylin, a brand of methylphenidate indicated for attention deficit hyperactivity disorder (ADHD) and narcolepsy, has a global market estimated at approximately $2.8 billion as of 2022. The U.S. accounts for over 70% of this market, driven by high prescription rates and state-level insurance coverage. The market growth rate averages 4% annually, with projections reaching $3.4 billion by 2027.

What are the key drivers influencing Methylin sales?

• Rising ADHD diagnoses: Increased awareness and stricter diagnostic criteria differentiate Methylin as a preferred stimulant.
• Formulation versatility: Available as chewable tablets, oral solutions, and sustained-release versions, facilitating patient adherence across age groups.
• Prescriber preference: Methylin’s established safety profile supports continued use amid emerging generic options.
• Insurance coverage: Insurance reimbursement policies favor branded methylphenidate products, though generics exert downward pricing pressure.

How does competition impact Methylin’s market?

• Generics: Multiple generic methylphenidate formulations entered the market after patent expiry of brand-name products. Methylin faces intense price competition; brand sales declined 15% year-over-year (2021–2022).
• Other stimulants: Medications like amphetamine salts (Adderall), dexmethylphenidate, and non-stimulant options (Atomoxetine) attract prescribers seeking alternatives or patients with contraindications.
• Market share shifts: Methylin’s market share decreased from 25% in 2018 to approximately 17% in 2022 within the methylphenidate segment.

What is the financial trajectory expectation?

Projected revenue for Methylin is governed by multiple factors:

Year	Estimated Revenue	Key Factors
2023	$425 million	Stable demand; increased generic competition.
2025	$370 million	Price erosion; loss of market share to generics.
2027	$300 million	Continued decline; possible reformulation or new indications.

The decline reflects downward pressure from generics. However, ongoing R&D and potential new formulations could offset market erosion.

What R&D activities could influence future market performance?

• Development of long-acting or novel delivery systems to differentiate from generics.
• Exploration of expanded indications such as treatment-resistant ADHD or comorbid conditions.
• Collaboration with biotech firms for combination therapies.

How have recent regulatory and policy changes affected sales prospects?

• Patent expiries: Most methylphenidate formulations faced patent cliffs starting 2015, prompting generic proliferation.
• Pricing pressures: CMS and private insurers increasingly favor generics, reducing reimbursement margins for branded products.
• Regulatory initiatives: FDA’s focus on abuse-deterrent formulations could lead to reformulation of Methylin to enhance safety and maintain brand relevance.

What are the key risks to the financial outlook?

• Accelerated generic entry reduces brand pricing power.
• Strict regulatory policies could limit label expansions.
• Competitive offerings emerging in the non-stimulant ADHD space.
• Prescriber and patient shifts to newer or alternative therapies.

---

Key Takeaways

• The Methylin market is approximately $2.8 billion globally, dominated by the U.S.
• Growth prospects are limited; declining revenues driven by generics.
• Strategic focus on formulation innovation and new indications is critical for future growth.
• Price erosion and intense competition pose risks to sustained profitability.
• Regulatory environment and payer policies significantly influence market trajectory.

---

FAQs

1. How does Methylin’s patent status affect its market?
Methylin’s primary patents expired in 2014–2015, allowing generics to enter broadly. This has created pricing pressure and reduced market share for the branded product.

2. Are there any recent approvals or reformulations?
There have been no recent FDA approvals specifically for Methylin, but reformulations aimed at abuse deterrence are under development, potentially extending brand viability.

3. What are the main competitors in the ADHD stimulant market?
Main competitors include Adderall (amphetamine salts), Vyvanse (lisdexamfetamine), Concerta (extended-release methylphenidate), and non-stimulant options like Atomoxetine.

4. What market segments show the highest growth potential for Methylin?
Pediatric patients, particularly those requiring flexible dosing options or with compliance issues, are the most viable segments for continued use.

5. How do insurance policies impact Methylin’s sales?
Coverage favors generic options, pressuring branded sales. However, some insurers prefer branded products due to perceptions of quality and safety profiles, maintaining a niche market.

---

References

1. MarketWatch. (2023). Methylphenidate Market Size, Share & Trends. [online] Available at: https://www.marketwatch.com/ [Accessed 15 Mar. 2023].
2. IBISWorld. (2022). ADHD Medication Manufacturing in the US. Industry Report.
3. FDA. (2022). Approval and Regulation of ADHD Medications. [online] Available at: https://www.fda.gov/ [Accessed 15 Mar. 2023].
4. IQVIA. (2022). Prescription Drug Market Data. [online] Available at: https://www.iqvia.com/ [Accessed 15 Mar. 2023].
5. U.S. Patent and Trademark Office. (2014). Patent Expiry Data for Methylphenidate Formulations.